Breast Cancer, Endometrial Cancer, Ovarian Cancer
Conditions
Keywords
breast cancer, endometrial Cancer, ovarian cancer, CTC heterogeneity, cancer stem cells, epithelial-mesenchymal transition, multicolor flow cytometry, liquid biopsy, circulating tumor cell
Brief summary
The study evaluates the level and molecular profiles of different CTC populations as markers for predicting the risk of developing hematogenous metastases and the effectiveness of treatment in patients with tumors of the female reproductive system (breast cancer, endometrial cancer, and ovarian cancer). The primary objective are: 1. To assess the presence and number of different populations of CTCs at different time points (before biopsy, before surgery, and after surgery). 2. To assess the relationships of different CTCs populations prior to treatment initiation with the effects of neoadjuvant chemotherapy and the risks of recurrence and metastases. 3. To assess the molecular profiles of different CTCs populations in the blood and in ascitic fluid. The secondary objective is to compare the multicolor flow cytometry results with data of ultrasound, CT and/or MRI, serum tumor markers, and immunohistochemical studies in patients with breast cancer, endometrial cancer and ovarian cancer
Detailed description
The overall goal is to study the diagnostic and prognostic efficacy of various CTC populations as liquid biopsy markers in tumors of the female reproductive system (breast cancer, endometrial cancer, and ovarian cancer). Phase I study: Determination of different populations of CTCs in blood and ascitic fluid (if any) prior to treatment. The main objectives of the study: 1. To assess the presence and number of different CTC populations at different time points (before biopsy and before surgery) using multicolor flow cytometry. 2. To assess the relationships between different CTCs populations prior to treatment initiation with the effects of neoadjuvant chemotherapy and the risks of recurrence and metastases. 3. To assess the molecular profiles of different CTCs populations in the blood and in ascitic fluid. Additional research tasks: To compare the multicolor flow cytometry results with the data of ultrasound, CT and/or MRI, serum tumor markers, and immunohistochemical studies in patients with breast cancer, endometrial cancer, and ovarian cancer Methodology: Open-label, exploratory, single centre study. Blood and ascitic fluid collected from subjects (if available)
Interventions
OTHERTaking 5 ml of venous blood at different time intervals
OTHERTaking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
Sponsors
Tomsk National Research Medical Center of the Russian Academy of Sciences
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is \> 18 years of age A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. * Clinical and radiological diagnosis of breast cancer or Ovarian cancer or Endometrial Cancer General satisfactory condition (according to the ECOG scale ≤2) Subject is capable to undergo the diagnostic investigations to be performed in the study * Informed consent
Exclusion criteria
* Active current autoimmune disease or history of autoimmune disease * Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) * Known HIV positive or chronically active hepatitis B or C The subject has multiple primary malignant tumors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CTC phenotype | 6 hours | Different populations of CTCs are evaluated by multicolor flow cytometry and may include: СTC, ascitic tumor cells with stemness features without EMT features; CTC, ascitic tumor cells without stemness and EMT features; CTC, ascitic tumor cells without stemness features and with EMT features; CTC, ascitic tumor cells with stemness features and EMT features; Atypical/hybrid cells without stemness features; Atypical cells. |
Countries
Russia
Contacts
PRINCIPAL_INVESTIGATOREvgeniya Kaigorodova
Tomsk NRMC
Outcome results
None listed